Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Sep 1;4(9):e2124331.
doi: 10.1001/jamanetworkopen.2021.24331.

Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine

Nathan E Richards  1 , Behnam Keshavarz  1 , Lisa J Workman  1 , Michael R Nelson  1 , Thomas A E Platts-Mills  1 , Jeffrey M Wilson  1
Affiliations
Comparative Study

Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine

Nathan E Richards et al. JAMA Netw Open. .

Abstract

This cohort study compares antibody responses in a cohort in which both BNT162b2 and mRNA-1273 COVID-19 vaccines were administered.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Platts-Mills and Wilson reported receiving assay support from Thermo-Fisher/Phadia outside the submitted work. Dr Wilson reported receiving consultancy fees from Thermo-Fisher/Phadia and funding for this project from the University of Virginia Manning COVID-19 Research Fund during the conduct of this study. Dr Wilson reported receiving ongoing salary support from AAAAI Faculty Development Award. No other disclosures were reported.

Figures

Figure.
Figure.. Levels of IgG to SARS-CoV-2 Spike RBD in an Employee Vaccine Cohort
Preboost is 14 to 28 days after the primary immunization and postboost is 7 to 31 days after the boost immunization. Data are presented as geometric means with 95% CI and comparisons with Mann-Whitney U test. The dotted lines denotes cutoff of assay, as previously described. Accounting for multiple comparisons, P < .0125 was considered as significant. aP < .001. bP < .05.
See this image and copyright information in PMC

References

    1. Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. ; COVE Study Group . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389 - DOI - PMC - PubMed
    1. Keshavarz B, Wiencek JR, Workman LJ, et al. . Quantitative measurement of IgG to severe acute respiratory syndrome coronavirus-2 proteins using ImmunoCAP. Int Arch Allergy Immunol. 2021;182(5):417-424. doi:10.1159/000514203 - DOI - PMC - PubMed
    1. Müller L, Andrée M, Moskorz W, et al. . Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis. 2021;ciab381. doi:10.1093/cid/ciab381 - DOI - PMC - PubMed
    1. Abu Jabal K, Ben-Amram H, Beiruti K, et al. . Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021;26(6):2100096. doi:10.2807/1560-7917.ES.2021.26.6.2100096 - DOI - PMC - PubMed

Publication types